-
Je něco špatně v tomto záznamu ?
A pilot randomized trial comparing long-term effects of red and white wines on biomarkers of atherosclerosis (in vino veritas: IVV trial)
M. Taborsky, P. Ostadal, M. Petrek,
Jazyk angličtina Země Slovensko
Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie
PubMed
22428764
DOI
10.4149/bll_2012_037
Knihovny.cz E-zdroje
- MeSH
- ateroskleróza diagnóza MeSH
- biologické markery krev MeSH
- HDL-cholesterol MeSH
- lidé MeSH
- víno analýza MeSH
- výzkumný projekt MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- randomizované kontrolované studie MeSH
- srovnávací studie MeSH
BACKGROUND: Since early 90', growing body of evidence indicates that the Mediterranean diet with mild to moderate consumption of wine, mostly red wine, has a protective effect on cardiovascular diseases. Several mechanisms have been discussed to participate in the beneficial effect of red wine, such as antioxidant or vasodilating activity. However, later it has been shown that also other alcoholic beverages have a protective effect on atherosclerosis. Up to now, data from the prospective, long-term, head-to-head comparisons of the effects of different drinks on markers of atherosclerosis are insufficient. METHODS: The IVV (in vino veritas) study is a long-term, prospective, multicenter, randomized trial comparing the effect of red and white wines on the markers of atherosclerosis. One hundred and twenty healthy subjects with mild to moderate risk of atherosclerosis will be randomized to regular consumption of red wine (Pinot Noir) or white wine (Chardonnay-Pinot) for one year. The primary endpoint is the level of HDL-cholesterol at one year, while secondary endpoints are levels of other markers of atherosclerosis (LDL-cholesterol, C-reactive protein, myeloperoxidase, advanced oxidation protein product, interleukins 6 and 18, matrix metalloproteinases, glutathione s-transferase, monocyte chemoattractant protein 1, soluble CD40L). CONCLUSION: The IVV trial is the first study focusing on the long-term prospective comparison of the effects of red and white wines consumption on HDL-cholesterol and other markers of atherosclerosis. Results of the IVV trial may extend our understanding of the widely discussed "French paradox" (Tab. 1, Ref. 21)
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12023984
- 003
- CZ-PrNML
- 005
- 20121206122412.0
- 007
- ta
- 008
- 120815s2012 xo f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.4149/bll_2012_037 $2 doi
- 035 __
- $a (PubMed)22428764
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xo
- 100 1_
- $a Taborsky, M $u Olomouc University Hospital, Olomouc, Czech Republic. milos.taborsky@fnol.cz
- 245 12
- $a A pilot randomized trial comparing long-term effects of red and white wines on biomarkers of atherosclerosis (in vino veritas: IVV trial) / $c M. Taborsky, P. Ostadal, M. Petrek,
- 520 9_
- $a BACKGROUND: Since early 90', growing body of evidence indicates that the Mediterranean diet with mild to moderate consumption of wine, mostly red wine, has a protective effect on cardiovascular diseases. Several mechanisms have been discussed to participate in the beneficial effect of red wine, such as antioxidant or vasodilating activity. However, later it has been shown that also other alcoholic beverages have a protective effect on atherosclerosis. Up to now, data from the prospective, long-term, head-to-head comparisons of the effects of different drinks on markers of atherosclerosis are insufficient. METHODS: The IVV (in vino veritas) study is a long-term, prospective, multicenter, randomized trial comparing the effect of red and white wines on the markers of atherosclerosis. One hundred and twenty healthy subjects with mild to moderate risk of atherosclerosis will be randomized to regular consumption of red wine (Pinot Noir) or white wine (Chardonnay-Pinot) for one year. The primary endpoint is the level of HDL-cholesterol at one year, while secondary endpoints are levels of other markers of atherosclerosis (LDL-cholesterol, C-reactive protein, myeloperoxidase, advanced oxidation protein product, interleukins 6 and 18, matrix metalloproteinases, glutathione s-transferase, monocyte chemoattractant protein 1, soluble CD40L). CONCLUSION: The IVV trial is the first study focusing on the long-term prospective comparison of the effects of red and white wines consumption on HDL-cholesterol and other markers of atherosclerosis. Results of the IVV trial may extend our understanding of the widely discussed "French paradox" (Tab. 1, Ref. 21)
- 650 _2
- $a ateroskleróza $x diagnóza $7 D050197
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a HDL-cholesterol $7 D008076
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a výzkumný projekt $7 D012107
- 650 _2
- $a víno $x analýza $7 D014920
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Ostadal, P
- 700 1_
- $a Petrek, M
- 773 0_
- $w MED00000845 $t Bratislavské lekárske listy $x 0006-9248 $g Roč. 113, č. 3 (2012), s. 156-8
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22428764 $y Pubmed
- 910 __
- $a ABA008 $b A 4 $c sign $y m
- 990 __
- $a 20120815 $b ABA008
- 991 __
- $a 20121206122445 $b ABA008
- 999 __
- $a ok $b bmc $g 946132 $s 781312
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 113 $c 3 $d 156-8 $i 0006-9248 $m Bratislavské lekárske listy $n Bratisl Lek Listy $x MED00000845
- LZP __
- $a Pubmed-20120815/12/02